Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Real-World Retrospective Study of Non-Transfusion Dependent Patients with Myelodysplastic Syndromes Treated with Luspatercept: A Healthcare Claims Database Study

Leslie A. Andritsos, Kirollos S. Hanna, Enrico Zanardo, Ali McBride, Victoria Barghout, Rui Song, Lynn Huynh, Derek Tang, Mihran Yenikomshian, Kashyap Patel

Blood (2023) 142 (Supplement 1): 3808.

https://doi.org/10.1182/blood-2023-173375

Published: 2023

Journal Articles

Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study

David L. Grinblatt, Gail J. Roboz, Daniel A. Pollyea, Mikkael A. Sekeres, Bart L. Scott, Karen Seiter, Amer M. Zeidan, Jay L. Patel, Guillermo Garcia-Manero, Rami S. Komrokji, Michael R. Savona, Irene S. Degutis, Pavel Kiselev, Edward Yu, Willem Heydendael, Ying Qiu, Sara Vergara, Ali McBride, Harry P. Erba

Blood (2023) 142 (Supplement 1): 593.

https://doi.org/10.1182/blood-2023-189963

Published: 2023

Journal Articles

Real-World Impact of Luspatercept on Patients with Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions and with Prior Exposure to Erythropoietin-Stimulating Agents: A United States Healthcare Claims Database Study

Kashyap Patel, Kirollos S. Hanna, Enrico Zanardo, Ali McBride, Victoria Barghout, Rui Song, Lynn Huynh, Derek Tang, Mihran Yenikomshian, Leslie A. Andritsos

Blood (2023) 142 (Supplement 1): 916.

https://doi.org/10.1182/blood-2023-173364

Published: 2023

Journal Articles

Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Lower-Risk Myelodysplastic Syndromes Who Have Been Treated with Luspatercept

Ralph Boccia, Hong Xiao, Dimana Miteva, Min Che, Tao Gu, Ali McBride, Mrudula B. Glassberg, Aylin Yucel

Blood (2023) 142 (Supplement 1): 7411.

https://doi.org/10.1182/blood-2023-173360

Published: 2023

Journal Articles

Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns

Sudipto Mukherjee, Cherrishe Brown-Bickerstaff, Ali McBride, Ajeet Gajra, Danielle Gentile, Angelica Falkenstein, Talia Miller, JaLyna Laney, Kristin M. Savill, Adeola Y. Makinde

Blood (2022) 140 (Supplement 1): 944–946.

https://doi.org/10.1182/blood-2022-156902

Published: 2022

Journal Articles

Real-World (RW) Evaluation of Acute Myeloid Leukemia (AML) Induction Therapies in the Community Setting: A Retrospective Evaluation of Outcomes of Intensive Chemotherapy, Venetoclax-Based Regimens, and Non-IC-Based Treatments

Keri Maher, Cherrishe Brown-Bickerstaff, Ali McBride, Ajeet Gajra, Djibril Liassou, Ying Qiu, Marné Garretson, JaLyna Laney, David Huggar, David Hughes

Blood (2022) 140 (Supplement 1): 13278–13279.

https://doi.org/10.1182/blood-2022-169762

Published: 2022

Journal Articles

Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

Michael Mauro, Ronald Paquette, Rüdiger Hehlmann, Loretta A. Williams, Stuart L. Goldberg, Mauricette Michallet, Carlo Gambacorti-Passerini, Derek Tang, Irene S. DeGutis, Ali McBride, Lori Parsons, Monica Z. Montelongo, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 9624–9625.

https://doi.org/10.1182/blood-2022-163080

Published: 2022

Journal Articles

Impact of Transfusions and Treatment Choice on Time Spent in Healthcare Facilities for Patients with Myelodysplastic Syndromes

Mikkael A. Sekeres, Guillermo Garcia-Manero, David L. Grinblatt, Rami S. Komrokji, Michael R. Savona, Harry P. Erba, Gail J. Roboz, Irene S. DeGutis, Pavel Kiselev, Edward Yu, Adeola Y. Makinde, Ali McBride, Bart L. Scott

Blood (2022) 140 (Supplement 1): 9818–9820.

https://doi.org/10.1182/blood-2022-158075

Published: 2022

Journal Articles

Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study

Jorge E. Cortes, Stuart L. Goldberg, Ronald Paquette, Loretta A. Williams, Rüdiger Hehlmann, Mauricette Michallet, Carlo Gambacorti-Passerini, Derek Tang, Irene S. DeGutis, Ali McBride, Lori Parsons, Monica Z. Montelongo, Michael Mauro

Blood (2022) 140 (Supplement 1): 3902–3903.

https://doi.org/10.1182/blood-2022-163063

Published: 2022

Journal Articles

Treatment Patterns and Outcomes of Patients with Primary or Secondary Acute Myeloid Leukemia By Type of Site (Academic or Community/Government): A CONNECT® Myeloid Registry Study

Bart L. Scott, Michael R. Savona, Gail J. Roboz, Karen Seiter, Daniel A. Pollyea, Irene S. DeGutis, Pavel Kiselev, Edward Yu, Ali McBride, Willem Heydendael, Harry P. Erba

Blood (2022) 140 (Supplement 1): 8923–8925.

https://doi.org/10.1182/blood-2022-158068

Published: 2022

Journal Articles

Treatment Patterns and Outcomes of Patients with NPM1 + Acute Myeloid Leukemia (AML) Enrolled in the CONNECT® Myeloid Disease Registry

Daniel A. Pollyea, Jaroslaw P. Maciejewski, Gail J. Roboz, Karen Seiter, Bart L. Scott, Irene S. DeGutis, Pavel Kiselev, Edward Yu, Ali McBride, Willem Heydendael, Harry P. Erba

Blood (2022) 140 (Supplement 1): 11844–11846.

https://doi.org/10.1182/blood-2022-156679

Published: 2022

Journal Articles

The Use of Fedratinib for Myelofibrosis As a Potential Bridge to Hematopoietic Stem Cell Transplantation after Ruxolitinib Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptom, and Hematologic Response

John Mascarenhas, Claire Harrison, Tammy Schuler, Djibril Liassou, Marné Garretson, Sankar Mahadevan, Ali McBride, Derek Tang, Irene S. DeGutis, Pranav Abraham, Aaron T. Gerds

Blood (2022) 140 (Supplement 1): 5276–5278.

https://doi.org/10.1182/blood-2022-156780

Published: 2022

Journal Articles

Cost-Effectiveness Analyses of First Line Ibrutinib Versus Acalabrutinib Versus Zanubrutinib Followed By Second Line Venetoclax Plus Rituximab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Neda Alrawashdh, Ali McBride, Ivo Abraham

Blood (2022) 140 (Supplement 1): 2155–2156.

https://doi.org/10.1182/blood-2022-156948

Published: 2022

Journal Articles

Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US

Sudipto Mukherjee, Kristin M. Savill, Ajeet Gajra, Danielle Gentile, Angelica Falkenstein, Talia Miller, JaLyna Laney, Ali McBride

Blood (2022) 140 (Supplement 1): 10998–11000.

https://doi.org/10.1182/blood-2022-156892

Published: 2022

Journal Articles

Treatment Patterns and Economic Burden Among Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A SEER-Medicare Analysis

Andrew M. Brunner, David Huggar, Ronda Copher, Zheng-Yi Zhou, Miriam L. Zichlin, Annika Anderson, Nathaniel Downes, Ali McBride

Blood (2021) 138 (Supplement 1): 4975.

https://doi.org/10.1182/blood-2021-145593

Published: 2021

Journal Articles

Comparative Effectiveness of Fedratinib and Pacritinib for the Treatment of Myelofibrosis in Patients with Low Platelet Counts: A Simulated Treatment Comparison Study

Patrick Daniele, Pranav Abraham, Arianna Kee, Gabriel Tremblay, Shelonitda Rose, Ali McBride

Blood (2021) 138 (Supplement 1): 5034.

https://doi.org/10.1182/blood-2021-145685

Published: 2021

Journal Articles

Healthcare Resource Utilization and Costs in US Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Intensive Induction Chemotherapy

David Huggar, Russell L. Knoth, Ronda Copher, Zhun Cao, Craig Lipkin, Ali McBride, Thomas W. LeBlanc

Blood (2021) 138 (Supplement 1): 4039.

https://doi.org/10.1182/blood-2021-148434

Published: 2021

Journal Articles

Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

John Mascarenhas, Aaron T. Gerds, Arianna Kee, Jonathan K. Kish, Pranav Abraham, Alexandrina Balanean, Jose Alberto Nadal, Djibril Liassou, Bruce A. Feinberg, Ali McBride, Claire N. Harrison

Blood (2021) 138 (Supplement 1): 1980.

https://doi.org/10.1182/blood-2021-145573

Published: 2021

Journal Articles

Meta-Analysis of Chemotherapy-Induced (Febrile) Neutropenia and Chemotherapy Disruptions Associated with Same-Day Versus Standard (24-72h) Pegfilgrastim Administration in Non-Hodgkin Lymphoma Patients

Neda Alrawashdh, Ali McBride, Ivo Abraham

Blood (2021) 138 (Supplement 1): 3011.

https://doi.org/10.1182/blood-2021-150989

Published: 2021

Journal Articles

Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure

Claire N. Harrison, John Mascarenhas, Pranav Abraham, Arianna Kee, Jose Alberto Nadal, Alexandrina Balanean, Ali McBride, Jonathan K. Kish, Djibril Liassou, Bruce A. Feinberg, Aaron T. Gerds

Blood (2021) 138 (Supplement 1): 3059.

https://doi.org/10.1182/blood-2021-145569

Published: 2021

NARROW

Real-World Retrospective Study of Non-Transfusion Dependent Patients with Myelodysplastic Syndromes Treated with Luspatercept: A Healthcare Claims Database Study

Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study

Real-World Impact of Luspatercept on Patients with Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions and with Prior Exposure to Erythropoietin-Stimulating Agents: A United States Healthcare Claims Database Study

Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Lower-Risk Myelodysplastic Syndromes Who Have Been Treated with Luspatercept

Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns

Real-World (RW) Evaluation of Acute Myeloid Leukemia (AML) Induction Therapies in the Community Setting: A Retrospective Evaluation of Outcomes of Intensive Chemotherapy, Venetoclax-Based Regimens, and Non-IC-Based Treatments

Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

Impact of Transfusions and Treatment Choice on Time Spent in Healthcare Facilities for Patients with Myelodysplastic Syndromes

Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study

Treatment Patterns and Outcomes of Patients with Primary or Secondary Acute Myeloid Leukemia By Type of Site (Academic or Community/Government): A CONNECT® Myeloid Registry Study

Treatment Patterns and Outcomes of Patients with NPM1 + Acute Myeloid Leukemia (AML) Enrolled in the CONNECT® Myeloid Disease Registry

The Use of Fedratinib for Myelofibrosis As a Potential Bridge to Hematopoietic Stem Cell Transplantation after Ruxolitinib Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptom, and Hematologic Response

Cost-Effectiveness Analyses of First Line Ibrutinib Versus Acalabrutinib Versus Zanubrutinib Followed By Second Line Venetoclax Plus Rituximab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US

Treatment Patterns and Economic Burden Among Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A SEER-Medicare Analysis

Comparative Effectiveness of Fedratinib and Pacritinib for the Treatment of Myelofibrosis in Patients with Low Platelet Counts: A Simulated Treatment Comparison Study

Healthcare Resource Utilization and Costs in US Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Intensive Induction Chemotherapy

Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

Meta-Analysis of Chemotherapy-Induced (Febrile) Neutropenia and Chemotherapy Disruptions Associated with Same-Day Versus Standard (24-72h) Pegfilgrastim Administration in Non-Hodgkin Lymphoma Patients

Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only